155 related articles for article (PubMed ID: 15707415)
1. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy.
Anglicheau D; Le Corre D; Lechaton S; Laurent-Puig P; Kreis H; Beaune P; Legendre C; Thervet E
Am J Transplant; 2005 Mar; 5(3):595-603. PubMed ID: 15707415
[TBL] [Abstract][Full Text] [Related]
2. Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients.
Miao LY; Huang CR; Hou JQ; Qian MY
Biopharm Drug Dispos; 2008 Jan; 29(1):1-5. PubMed ID: 17941052
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids.
Mourad M; Mourad G; Wallemacq P; Garrigue V; Van Bellingen C; Van Kerckhove V; De Meyer M; Malaise J; Eddour DC; Lison D; Squifflet JP; Haufroid V
Transplantation; 2005 Oct; 80(7):977-84. PubMed ID: 16249748
[TBL] [Abstract][Full Text] [Related]
4. Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients.
Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
Transplantation; 2011 Dec; 92(12):1342-7. PubMed ID: 22094953
[TBL] [Abstract][Full Text] [Related]
5. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
6. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients.
Sam WJ; Chamberlain CE; Lee SJ; Goldstein JA; Hale DA; Mannon RB; Kirk AD; Hon YY
Transplantation; 2012 Nov; 94(9):971-7. PubMed ID: 23073467
[TBL] [Abstract][Full Text] [Related]
7. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
8. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
11. CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients.
Li Y; Yan L; Shi Y; Bai Y; Tang J; Wang L
Springerplus; 2015; 4():637. PubMed ID: 26543771
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
Lee J; Huang H; Chen Y; Lu X
Biopharm Drug Dispos; 2014 Apr; 35(3):164-72. PubMed ID: 24285256
[TBL] [Abstract][Full Text] [Related]
13. Effect of CYP3A4*22, POR*28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients.
Woillard JB; Kamar N; Coste S; Rostaing L; Marquet P; Picard N
Clin Chem; 2013 Dec; 59(12):1761-9. PubMed ID: 23974086
[TBL] [Abstract][Full Text] [Related]
14. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients.
Qiu XY; Jiao Z; Zhang M; Zhong LJ; Liang HQ; Ma CL; Zhang L; Zhong MK
Eur J Clin Pharmacol; 2008 Nov; 64(11):1069-84. PubMed ID: 18636247
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
17. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
[TBL] [Abstract][Full Text] [Related]
18. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation.
Azarpira N; Aghdaie MH; Behzad-Behbahanie A; Geramizadeh B; Behzadi S; Malekhoseinie SA; Raisjalal GH; Rahsaz M; Pourgholami A; Sagheb F
Exp Clin Transplant; 2006 Jun; 4(1):416-9. PubMed ID: 16827636
[TBL] [Abstract][Full Text] [Related]
19. Effect of Multidrug-Resistant 1 (MDR1) and CYP3A4*1B Polymorphisms on Cyclosporine-Based Immunosuppressive Therapy in Renal Transplant Patients.
Kotowski MJ; Bogacz A; Bartkowiak-Wieczorek J; Tejchman K; Dziewanowski K; Ostrowski M; Czerny B; Grześkowiak E; Machaliński B; Sieńko J
Ann Transplant; 2019 Feb; 24():108-114. PubMed ID: 30799432
[TBL] [Abstract][Full Text] [Related]
20. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
